Gang Wang1, Fang Wang2, Peter G Gibson3,4,5, Michael Guo4, Wei-Jie Zhang6, Peng Gao7, Hong-Ping Zhang1, Erin S Harvey5, Hui Li6, Jie Zhang7. 1. Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Centre for Biotherapy, Chengdu 610041, China. 2. Norman Bethune College of Medicine, Jilin University, Changchun 130021, China. 3. Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, Priority Research Centre for Healthy Lungs, New Lambton Heights, NSW, Australia. 4. Australasian Severe Asthma Network, Clinical Management, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia. 5. Australasian Severe Asthma Network, School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia. 6. Department of Respiratory and Critical Care Medicine, The People's Hospital of Jilin Province, Changchun, Jilin 130000, China. 7. Department of Respiratory and Critical Care Medicine, The 2nd Affiliated Hospital, Jilin University, Changchun, Jilin 130041, China.
Abstract
BACKGROUND: Severe asthma is largely unexplored in the Chinese population. Patients with asthma underwent systematic evaluation, by investigating the characteristics of uncontrolled asthma and of asthma treated with three different controller therapies. METHODS: This multi-centre, real-world study was conducted from March 2014 to September 2015. Adults with stable asthma underwent assessment of medication use, asthma control, quality of life, psychological symptoms, work productivity and activity impairment, bronchodilator response and sputum induction. RESULTS: Participants (n=379) had a mean (SD) age of 47.4 (14.0) years, and 57.0% were female. There were 14.8% (n=56) of patients receiving treatment with Step 4/5 as severe asthma, but only 13 (3.4%) met ERS/ATS severe refractory asthma criteria. The patients with severe asthma usually used triple controller therapy: ICS/LABA, additional leukotriene modifier or theophylline, and reported better asthma control. Two fifths of patients (n=147) had uncontrolled asthma, with worse symptoms, psychological symptoms (both P<0.001), health-related work productivity and activity impairment, increased eosinophilic inflammation in sputum [1.68% (0.0, 17.1%) vs. 0.2% (0.0, 1.3%), P<0.0001] and more exacerbations (P<0.05). Multiple regression analysis indicated that triple controller therapy significantly reduced the risk of uncontrolled asthma [OR =0.32, 95% CI =(0.14, 0.75)]. CONCLUSIONS: Although there is a relatively low proportion of severe refractory asthma based on ERS/ATS criteria, two of five patients with asthma in China are uncontrolled, displaying more psychological symptoms and reduced work productivity. Substantial gain in asthma control is obtained by triple controller therapy and this may be a promising therapeutic option for persistent asthma.
BACKGROUND: Severe asthma is largely unexplored in the Chinese population. Patients with asthma underwent systematic evaluation, by investigating the characteristics of uncontrolled asthma and of asthma treated with three different controller therapies. METHODS: This multi-centre, real-world study was conducted from March 2014 to September 2015. Adults with stable asthma underwent assessment of medication use, asthma control, quality of life, psychological symptoms, work productivity and activity impairment, bronchodilator response and sputum induction. RESULTS:Participants (n=379) had a mean (SD) age of 47.4 (14.0) years, and 57.0% were female. There were 14.8% (n=56) of patients receiving treatment with Step 4/5 as severe asthma, but only 13 (3.4%) met ERS/ATS severe refractory asthma criteria. The patients with severe asthma usually used triple controller therapy: ICS/LABA, additional leukotriene modifier or theophylline, and reported better asthma control. Two fifths of patients (n=147) had uncontrolled asthma, with worse symptoms, psychological symptoms (both P<0.001), health-related work productivity and activity impairment, increased eosinophilic inflammation in sputum [1.68% (0.0, 17.1%) vs. 0.2% (0.0, 1.3%), P<0.0001] and more exacerbations (P<0.05). Multiple regression analysis indicated that triple controller therapy significantly reduced the risk of uncontrolled asthma [OR =0.32, 95% CI =(0.14, 0.75)]. CONCLUSIONS: Although there is a relatively low proportion of severe refractory asthma based on ERS/ATS criteria, two of five patients with asthma in China are uncontrolled, displaying more psychological symptoms and reduced work productivity. Substantial gain in asthma control is obtained by triple controller therapy and this may be a promising therapeutic option for persistent asthma.
Entities:
Keywords:
Severe asthma; controller therapy; uncontrolled asthma
Authors: Giorgio Ciprandi; Irene Schiavetti; Elena Rindone; Fabio L M Ricciardolo Journal: Ann Allergy Asthma Immunol Date: 2015-09-29 Impact factor: 6.347
Authors: Hong Lin Li; Xiao Li He; Bing Miao Liang; Hong Ping Zhang; Yan Wang; Gang Wang Journal: Allergy Asthma Proc Date: 2015 Nov-Dec Impact factor: 2.587
Authors: Kian Fan Chung; Sally E Wenzel; Jan L Brozek; Andrew Bush; Mario Castro; Peter J Sterk; Ian M Adcock; Eric D Bateman; Elisabeth H Bel; Eugene R Bleecker; Louis-Philippe Boulet; Christopher Brightling; Pascal Chanez; Sven-Erik Dahlen; Ratko Djukanovic; Urs Frey; Mina Gaga; Peter Gibson; Qutayba Hamid; Nizar N Jajour; Thais Mauad; Ronald L Sorkness; W Gerald Teague Journal: Eur Respir J Date: 2013-12-12 Impact factor: 16.671
Authors: Xue Mei Fang; Ying Liu; Ji Wang; Xin Zhang; Lei Wang; Li Zhang; Hong Ping Zhang; Lei Liu; Dan Huang; Dan Liu; Ke Deng; Feng Ming Luo; Hua Jing Wan; Wei Min Li; Gang Wang; Brian G Oliver Journal: Lung Date: 2022-09-26 Impact factor: 3.777
Authors: Ying Liu; Xin Zhang; Li Zhang; Brian G Oliver; Hong Guang Wang; Zhi Peng Liu; Zhi Hong Chen; Lisa Wood; Alan Chen-Yu Hsu; Min Xie; Vanessa McDonald; Hua Jing Wan; Feng Ming Luo; Dan Liu; Wei Min Li; Gang Wang Journal: Allergy Asthma Immunol Res Date: 2022-07 Impact factor: 5.096